市場調査レポート

商品コード

1563119

バイオディフェンスの世界市場：疾病タイプ・治療・地域別の予測 (～2030年)

Global Biodefense Market Research Report Information by Disease Type by Treatment, by Region - Forecast till 2030

出版日: 2024年08月10日
発行: Market Research Future
ページ情報: 英文 115 Pages
納期: 即納可能

価格

PDF & Excel (Single User License)

USD 4,950 710,671円

レポートPDF、Excelを1名のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。

PDF & Excel (Multi User License)

USD 5,950 854,241円

レポートPDF、Excelを同一企業内の最大15名がご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。

PDF & Excel (Enterprise License)

USD 7,250 1,040,882円

レポートPDF、Excelを同一企業内のすべての方がご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDF、Excelの印刷回数に制限はありません。印刷したもののご利用はPDFのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=143.57円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

バイオディフェンスの市場規模は予測期間中にCAGR 7.01％で成長すると予測されています。

潜在的なバイオテロ攻撃に備え、各国政府はワクチンのR&Dに多大な資源を投入しています。あらゆる形態のバイオテロに備えるための政府の取り組みにより、バイオディフェンス市場で事業を展開する製薬企業には事業拡大の大きな機会がもたらされています。さらに、世界の政府が生物防御能力を向上させるためのイニシアチブを実施しています。バイオディフェンス市場は、R&D、準備計画、インフラ整備、ワクチンや医薬品の調達に対する資金提供の増加により成長を遂げています。

地域別展望

2023年には、北米のバイオディフェンス市場が最大の市場シェアを示しました。これは、同地域でHIV、ウイルス性肝炎、インフルエンザなどの感染症が流行しているためです。米国疾病予防管理センター (CDC) は、2021年に米国で約900万人がインフルエンザウイルスと診断されたと推計しています。抗菌薬耐性が増加の一途をたどる中、この動向は今後も続くと予想されています。こうした感染症と闘うための安価な診断検査、ワクチン、治療薬に対する需要の高まりが市場を牽引すると予測されています。

欧州のバイオディフェンス市場は慢性疾患の増加やバイオディフェンス対策のR&D活動の活発化から、2番目に大きなシェアを占めています。

アジア太平洋のバイオディフェンス市場は、2023年から2032年にかけて大きく成長すると予測されています。同市場の成長に拍車をかけている主な要因は、同地域全体の患者数の増加です。この地域の消費者は、インフルエンザやCOVID-19を含む感染症の増加により、大きな健康リスクに直面しています。

当レポートでは、世界のバイオディフェンスの市場を調査し、市場の定義と概要、市場成長への各種影響因子の分析、市場規模の推移・予測、各種区分・地域別の内訳、競合環境、主要企業のプロファイルなどをまとめています。

LIST OF TABLES

TABLE 1 LIST OF ASSUMPTIONS & LIMITATIONS
TABLE 2 BIODEFENSE BUDGET, BY REGION, 2023 (USD MILLION)
TABLE 3 GLOBAL BIODEFENSE MARKET, 2019-2030 (USD MILLION)
TABLE 4 GLOBAL BIODEFENSE MARKET, BY REGION, 2019-2030 (USD MILLION)
TABLE 5 NORTH AMERICA: BIODEFENSE MARKET, BY COUNTRY, 2019-2030 (USD MILLION)
TABLE 6 NORTH AMERICA: BIODEFENSE MARKET, BY DISEASE TYPE, 2019-2030 (USD MILLION)
TABLE 7 NORTH AMERICA: BIODEFENSE MARKET, BY TREATMENT, 2019-2030 (USD MILLION)
TABLE 8 NORTH AMERICA: BIODEFENSE MARKET, FOR MEDICATION, BY TYPE 2019-2030 (USD MILLION)
TABLE 9 US: BIODEFENSE MARKET, BY DISEASE TYPE, 2019-2030 (USD MILLION)
TABLE 10 US: BIODEFENSE MARKET, BY TREATMENT, 2019-2030 (USD MILLION)
TABLE 11 US: BIODEFENSE MARKET, FOR MEDICATION, BY TYPE,2019-2030 (USD MILLION)
TABLE 12 CANADA: BIODEFENSE MARKET, BY DISEASE TYPE, 2019-2030 (USD MILLION)
TABLE 13 CANADA: BIODEFENSE MARKET, BY TREATMENT, 2019-2030 (USD MILLION)
TABLE 14 CANADA: BIODEFENSE MARKET, FOR MEDICATION, BY TYPE, 2019-2030 (USD MILLION)
TABLE 15 EUROPE: BIODEFENSE MARKET, BY COUNTRY, 2019-2030 (USD MILLION)
TABLE 16 EUROPE: BIODEFENSE MARKET, BY DISEASE TYPE, 2019-2030 (USD MILLION)
TABLE 17 EUROPE: BIODEFENSE MARKET, BY TREATMENT, 2019-2030 (USD MILLION)
TABLE 18 EUROPE: BIODEFENSE MARKET, FOR MEDICATION, BY TYPE, 2019-2030 (USD MILLION)
TABLE 19 GERMANY: BIODEFENSE MARKET, BY DISEASE TYPE, 2019-2030 (USD MILLION)
TABLE 20 GERMANY: BIODEFENSE MARKET, BY TREATMENT, 2019-2030 (USD MILLION)
TABLE 21 GERMANY: BIODEFENSE MARKET, FOR MEDICATION, BY TYPE, 2019-2030 (USD MILLION)
TABLE 22 UK: BIODEFENSE MARKET, BY DISEASE TYPE, 2019-2030 (USD MILLION)
TABLE 23 UK: BIODEFENSE MARKET, BY TREATMENT, 2019-2030 (USD MILLION)
TABLE 24 UK: BIODEFENSE MARKET, FOR MEDICATION, BY TYPE, 2019-2030 (USD MILLION)
TABLE 25 FRANCE: BIODEFENSE MARKET, BY DISEASE TYPE, 2019-2030 (USD MILLION)
TABLE 26 FRANCE: BIODEFENSE MARKET, BY TREATMENT, 2019-2030 (USD MILLION)
TABLE 27 FRANCE: BIODEFENSE MARKET, FOR MEDICATION, BY TYPE, 2019-2030 (USD MILLION)
TABLE 28 ITALY: BIODEFENSE MARKET, BY DISEASE TYPE, 2019-2030 (USD MILLION)
TABLE 29 ITALY: BIODEFENSE MARKET, BY TREATMENT, 2019-2030 (USD MILLION)
TABLE 30 ITALY: BIODEFENSE MARKET, FOR MEDICATION, BY TYPE, 2019-2030 (USD MILLION)
TABLE 31 SPAIN: BIODEFENSE MARKET, BY DISEASE TYPE, 2019-2030 (USD MILLION)
TABLE 32 SPAIN: BIODEFENSE MARKET, BY TREATMENT, 2019-2030 (USD MILLION)
TABLE 33 SPAIN: BIODEFENSE MARKET, FOR MEDICATION, BY TYPE, 2019-2030 (USD MILLION)
TABLE 34 REST OF EUROPE: BIODEFENSE MARKET, BY DISEASE TYPE, 2019-2030 (USD MILLION)
TABLE 35 REST OF EUROPE: BIODEFENSE MARKET, BY TREATMENT, 2019-2030 (USD MILLION)
TABLE 36 REST OF EUROPE: BIODEFENSE MARKET, FOR MEDICATION, BY TYPE, 2019-2030 (USD MILLION)
TABLE 37 ASIA-PACIFIC: BIODEFENSE MARKET, BY COUNTRY, 2019-2030 (USD MILLION)
TABLE 38 ASIA-PACIFIC: BIODEFENSE MARKET, BY DISEASE TYPE, 2019-2030 (USD MILLION)
TABLE 39 ASIA-PACIFIC: BIODEFENSE MARKET BY TREATMENT, 2019-2030 (USD MILLION)
TABLE 40 ASIA-PACIFIC: BIODEFENSE MARKET FOR MEDICATION, BY TYPE, 2019-2030 (USD MILLION)
TABLE 41 JAPAN: BIODEFENSE MARKET, BY DISEASE TYPE, 2019-2030 (USD MILLION)
TABLE 42 JAPAN: BIODEFENSE MARKET BY TREATMENT, 2019-2030 (USD MILLION)
TABLE 43 JAPAN: BIODEFENSE MARKET FOR MEDICATION, BY TYPE, 2019-2030 (USD MILLION)
TABLE 44 INDIA: BIODEFENSE MARKET, BY DISEASE TYPE, 2019-2030 (USD MILLION)
TABLE 45 INDIA: BIODEFENSE MARKET BY TREATMENT, 2019-2030 (USD MILLION)
TABLE 46 INDIA: BIODEFENSE MARKET FOR MEDICATION, BY TYPE, 2019-2030 (USD MILLION)
TABLE 47 SOUTH KOREA: BIODEFENSE MARKET, BY DISEASE TYPE, 2019-2030 (USD MILLION)
TABLE 48 SOUTH KOREA: BIODEFENSE MARKET BY TREATMENT, 2019-2030 (USD MILLION)
TABLE 49 SOUTH KOREA: BIODEFENSE MARKET FOR MEDICATION, BY TYPE, 2019-2030 (USD MILLION)
TABLE 50 AUSTRALIA: BIODEFENSE MARKET, BY DISEASE TYPE, 2019-2030 (USD MILLION)
TABLE 51 AUSTRALIA: BIODEFENSE MARKET BY TREATMENT, 2019-2030 (USD MILLION)
TABLE 52 AUSTRALIA: BIODEFENSE MARKET FOR MEDICATION, BY TYPE, 2019-2030 (USD MILLION)
TABLE 53 REST OF ASIA-PACIFIC: BIODEFENSE MARKET, BY DISEASE TYPE, 2019-2030 (USD MILLION)
TABLE 54 REST OF ASIA-PACIFIC: BIODEFENSE MARKET BY TREATMENT, 2019-2030 (USD MILLION)
TABLE 55 REST OF ASIA-PACIFIC: BIODEFENSE MARKET FOR MEDICATION, BY TYPE, 2019-2030 (USD MILLION)
TABLE 56 REST OF THE WORLD: BIODEFENSE MARKET, BY COUNTRY, 2019-2030 (USD MILLION)
TABLE 57 REST OF THE WORLD: BIODEFENSE MARKET, BY DISEASE TYPE, 2019-2030 (USD MILLION)
TABLE 58 REST OF THE WORLD: BIODEFENSE MARKET BY TREATMENT, 2019-2030 (USD MILLION)
TABLE 59 REST OF THE WORLD: BIODEFENSE MARKET FOR MEDICATION, BY TYPE, 2019-2030 (USD MILLION)
TABLE 60 MIDDLE EAST: BIODEFENSE MARKET, BY DISEASE TYPE, 2019-2030 (USD MILLION)
TABLE 61 MIDDLE EAST: BIODEFENSE MARKET BY TREATMENT, 2019-2030 (USD MILLION)
TABLE 62 MIDDLE EAST: BIODEFENSE MARKET FOR MEDICATION, BY TYPE, 2019-2030 (USD MILLION)
TABLE 63 AFRICA: BIODEFENSE MARKET, BY DISEASE TYPE, 2019-2030 (USD MILLION)
TABLE 64 AFRICA: BIODEFENSE MARKET BY TREATMENT, 2019-2030 (USD MILLION)
TABLE 65 AFRICA: BIODEFENSE MARKET FOR MEDICATION, BY TYPE, 2019-2030 (USD MILLION)
TABLE 66 LATIN AMERICA: BIODEFENSE MARKET, BY DISEASE TYPE, 2019-2030 (USD MILLION)
TABLE 67 LATIN AMERICA: BIODEFENSE MARKET BY TREATMENT, 2019-2030 (USD MILLION)
TABLE 68 LATIN AMERICA: BIODEFENSE MARKET FOR MEDICATION, BY TYPE, 2019-2030 (USD MILLION)
TABLE 69 MAJOR PLAYERS IN GLOBAL BIODEFENSE MARKET
TABLE 1 MOST ACTIVE PLAYER IN GLOBAL BIODEFENSE MARKET
TABLE 2 PRODUCT LAUNCH/ PRODUCT APPROVAL
TABLE 3 PARTNERSHIP/ COLLABORATION /AGREEMENT
TABLE 4 ACQUISITION/EXPANSION/INVESTMENT
TABLE 5 EMERGENT: PRODUCTS OFFERED
TABLE 6 EMERGENT: KEY DEVELOPMENTS
TABLE 7 BAVARIAN NORDIC: PRODUCTS OFFERED
TABLE 8 BAVARIAN NORDIC: KEY DEVELOPMENTS
TABLE 9 ALTIMMUNE: PRODUCTS OFFERED
TABLE 10 DYNAVAX TECHNOLOGIES: PRODUCTS OFFERED
TABLE 11 DYNAVAX TECHNOLOGIES: KEY DEVELOPMENTS
TABLE 12 SIGA TECHNOLOGIES: PRODUCTS OFFERED
TABLE 13 SIGA TECHNOLOGIES: KEY DEVELOPMENTS
TABLE 14 ELUSYS THERAPEUTICS, INC.: PRODUCTS OFFERED
TABLE 15 ELUSYS THERAPEUTICS, INC.: KEY DEVELOPMENTS
TABLE 16 FABENTECH BIOTECH: PRODUCTS OFFERED
TABLE 17 FABENTECH BIOTECH: KEY DEVELOPMENTS
TABLE 18 CLEVELAND BIOLABS, INC.: PRODUCTS OFFERED
TABLE 19 OLOGY BIOSERVICES, INC.: PRODUCTS OFFERED
TABLE 20 OLOGY BIOSERVICES, INC.: KEY DEVELOPMENTS
TABLE 21 NOVAVAX, INC.: PRODUCTS OFFERED
TABLE 22 NOVAVAX, INC.: KEY DEVELOPMENTS

LIST OF FIGURES

FIGURE 1 GLOBAL BIODEFENSE MARKET STRUCTURE
FIGURE 2 BOTTOM-UP AND TOP-DOWN APPROACHES
FIGURE 3 MARKET DYNAMICS: GLOBAL BIODEFENSE MARKET
FIGURE 4 DRIVER IMPACT ANALYSIS
FIGURE 5 RESTRAINT IMPACT ANALYSIS
FIGURE 6 VALUE CHAIN ANALYSIS: GLOBAL BIODEFENSE MARKET
FIGURE 7 PORTER'S FIVE FORCES ANALYSIS: GLOBAL BIODEFENSE MARKET
FIGURE 8 GLOBAL BIODEFENSE MARKET; DISEASE TYPE SEGMENT ATTRACTIVENESS, (USD MILLION)
FIGURE 9 GLOBAL BIODEFENSE MARKET; TREATMENT SEGMENT ATTRACTIVENESS, (USD MILLION)
FIGURE 10 GLOBAL BIODEFENSE MARKET SHARE, BY REGION, 2023 (% SHARE)
FIGURE 11 GLOBAL BIODEFENSE MARKET, BY REGION, 2023 & 2030 (USD MILLION)
FIGURE 12 NORTH AMERICA MARKET ANALYSIS: BIODEFENSE MARKET, 2019-2023(USD MILLION)
FIGURE 13 NORTH AMERICA: BIODEFENSE MARKET SHARE, BY COUNTRY, 2023 (% SHARE)
FIGURE 14 NORTH AMERICA: BIODEFENSE MARKET, BY COUNTRY, 2023 & 2030 (USD MILLION)
FIGURE 15 EUROPE MARKET ANALYSIS: BIODEFENSE MARKET, 2019-2023(USD MILLION)
FIGURE 16 EUROPE: BIODEFENSE MARKET SHARE, BY COUNTRY, 2023 (% SHARE)
FIGURE 17 EUROPE: BIODEFENSE MARKET, BY COUNTRY, 2023 & 2030 (USD MILLION)
FIGURE 18 ASIA-PACIFIC MARKET ANALYSIS: BIODEFENSE MARKET, 2019-2030 (USD MILLION)
FIGURE 19 ASIA-PACIFIC: BIODEFENSE MARKET, BY COUNTRY, 2019 & 2030 (USD MILLION)
FIGURE 20 ASIA-PACIFIC: BIODEFENSE MARKET SHARE (%), BY COUNTRY,
FIGURE 21 REST OF THE WORLD MARKET ANALYSIS: BIODEFENSE MARKET, 2019-2030 (USD MILLION)
FIGURE 22 REST OT THE WORLD: BIODEFENSE MARKET, BY REGION, 2019 & 2030 (USD MILLION)
FIGURE 23 REST OF THE WORLD: BIODEFENSE MARKET SHARE (%), BY COUNTRY,
FIGURE 24 BENCHMARKING OF MAJOR COMPETITORS
FIGURE 25 MAJOR STRATEGY ADOPTED BY KEY PLAYERS IN GLOBAL BIODEFENSE MARKET
FIGURE 26 GLOBAL BIODEFENSE MARKET: COMPETITIVE LANDSCAPE
FIGURE 27 MAJOR PLAYERS SALES,
FIGURE 28 MAJOR PLAYERS R&D EXPENDITURE,
FIGURE 29 EMERGENT: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 30 EMERGENT: SWOT ANALYSIS
FIGURE 31 BAVARIAN NORDIC: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 32 BAVARIAN NORDIC: SWOT ANALYSIS
FIGURE 33 ALTIMMUNE: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 34 DYNAVAX TECHNOLOGIES: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 35 SIGA TECHNOLOGIES: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 36 SIGA TECHNOLOGIES: SWOT ANALYSIS
FIGURE 37 FABENTECH BIOTECH: SWOT ANALYSIS
FIGURE 38 CLEVELAND BIOLABS, INC.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 39 NOVAVAX, INC.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 40 NOVAVAX, INC.: SWOT ANALYSIS

Product Code: MRFR/HC/20601-CR

Global Biodefense Market Research Report Information by Disease Type (Anthrax, Smallpox, Botulism, Influenza, Radiation/Nuclear, And Others) by Treatment (Vaccination, And Medication), by Region (North America, Europe, Asia-Pacific, and Rest of the World) - Forecast till 2030

Market Overview

During the forecast period, the Biodefense Market industry is anticipated to grow at a compound annual growth rate (CAGR) of 7.01%.

In preparation for potential bioterrorism attacks, governments are allocating substantial resources to vaccine research and development. Pharmaceutical companies that operate in the biodefense market have been presented with substantial opportunities to expand as a result of government initiatives to prepare for any form of bioterrorism. Additionally, governments worldwide are implementing initiatives to improve their biodefense capabilities. The biodefense market is experiencing growth because of increased funding for research and development, preparedness planning, infrastructure development, and the procurement of vaccines and medications.

Market segment insights

Anthrax, smallpox, botulism, influenza, radiation/nuclear, and other diseases comprise the Biodefense Market segmentation organized by disease type.

The segmentation of the Biodefense Market is based on the treatment, which includes vaccination and medication.

Regional Perspectives

The market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World by region. In 2023, the North American Biodefense market held the greatest market share. This is a result of the increasing prevalence of infectious diseases in the region, including HIV, viral hepatitis, and influenza. For example, the Centers for Disease Control and Prevention (CDC) estimated that approximately 9 million individuals in the United States were diagnosed with the influenza virus in 2021. This trend is anticipated to continue as antimicrobial resistance continues to increase. Furthermore, the market is anticipated to be driven by the increasing demand for affordable diagnostic tests, vaccines, and therapeutics to combat these infectious diseases.

The second-largest market share in the Europe Biodefense market is attributed to the increasing prevalence of chronic diseases and the increase in research and development activities for biodefense solutions throughout the region. Additionally, the German biodefense market was identified as having the greatest market share, while the Rest of Europe biodefense market is anticipated to be the fastest-growing market in the European region.

It is anticipated that the Asia-Pacific Biodefense market will experience substantial growth from 2023 to 2032. The primary factor fueling the market's growth is the rise in the prevalence of the patient population throughout the region. The region's consumers are facing a significant health risk due to the widespread epidemics of infectious diseases, including influenza and Covid-19, as well as the rise in the number of reported infections of communicable diseases. Moreover, the Japan Biodefense market is anticipated to have the highest market share, while the Rest of Asia-Pacific Biodefense market is anticipated to be the fastest-growing market in the Asia-Pacific region.

The Middle East, Africa, and Latin America comprise the Rest of the World. An increase in the prevalence of infectious diseases, including influenza and Covid-19, is expected to drive growth in the biodefense market in the regions.

Major Players

Emergent (US), Novavax, Inc. (US), Fabentech Biotech (France), SIGA Technologies (US), Dynavax Technologies (US), Altimmune (US), Bavarian Nordic (Denmark), Elusys Therapeutics, Inc. (US), Cleveland Biolabs, Inc. (US), and Ology Bioservices (US) are among the key companies in the Biodefense Market.

1 EXECUTIVE SUMMARY

1.1 OVERVIEW
- 1.1.1 MARKET SYNOPSIS

2 MARKET INTRODUCTION

2.1 DEFINITION
2.2 SCOPE OF THE STUDY
2.3 RESEARCH OBJECTIVE
2.4 MARKET STRUCTURE
2.5 LIST OF ASSUMPTIONS

3 RESEARCH METHODOLOGY

3.1 OVERVIEW
3.2 DATA MINING
3.3 SECONDARY RESEARCH
3.4 PRIMARY RESEARCH
- 3.4.1 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS
- 3.4.2 BREAKDOWN OF PRIMARY RESPONDENTS
3.5 FORECASTING TECHNIQUES
3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION
- 3.6.1 BOTTOM-UP APPROACH
- 3.6.2 TOP-DOWN APPROACH
3.7 DATA TRIANGULATION
3.8 VALIDATION

4 MARKET DYNAMICS

4.1 OVERVIEW
4.2 DRIVERS
- 4.2.1 INCREASING GOVERNMENT INITIATIVES AND FUNDING
- 4.2.2 RISE IN DEMAND FOR VACCINES
4.3 RESTRAINTS
- 4.3.1 LOW MARKET PENETRATION IN DEVELOPING AND UNDERDEVELOPED COUNTRIES
4.4 OPPORTUNITIES
- 4.4.1 TECHNOLOGICAL ADVANCEMENT

5 MARKET FACTOR ANALYSIS

5.1 VALUE CHAIN ANALYSIS
- 5.1.1 R&D & DESIGNING
- 5.1.2 MANUFACTURING
- 5.1.3 DISTRIBUTION & SALES
- 5.1.4 POST-SALES MONITORING
5.2 PORTER'S FIVE FORCES MODEL
- 5.2.1 THREAT OF NEW ENTRANTS
- 5.2.2 BARGAINING POWER OF SUPPLIERS
- 5.2.3 THREAT OF SUBSTITUTES
- 5.2.4 BARGAINING POWER OF BUYERS
- 5.2.5 INTENSITY OF RIVALRY
5.3 IMPACT OF COVID-19 ON THE GLOBAL BIODEFENSE MARKET
- 5.3.1 IMPACT ON SUPPLY CHAIN
- 5.3.2 IMPACT ON PRODUCTION
- 5.3.3 IMPACT ON REGIONS
- 5.3.4 IMPACT ON PRICING
5.4 AUTHORITIES BUDGET AND FINANCING PROGRAMS FOR BIODEFENSE BY REGION

6 GLOBAL BIODEFENSE MARKET, BY DISEASE TYPE

6.1 OVERVIEW
6.2 ANTHRAX
6.3 SMALL POX
6.4 BOTULISM
6.5 INFLUENZA
6.6 RADIATION/NUCLEAR
6.7 OTHERS

7 GLOBAL BIODEFENSE MARKET, BY TREATMENT

7.1 OVERVIEW
7.2 VACCINATION
7.3 MEDICATION

8 GLOBAL BIODEFENSE MARKET, BY REGION

8.1 GLOBAL OVERVIEW
8.2 NORTH AMERICA
- 8.2.1 US
- 8.2.2 CANADA
8.3 EUROPE
- 8.3.1 GERMANY
- 8.3.2 UK
- 8.3.3 FRANCE
- 8.3.4 ITALY
- 8.3.5 SPAIN
- 8.3.6 REST OF EUROPE
8.4 ASIA-PACIFIC
- 8.4.1 JAPAN
- 8.4.2 INDIA
- 8.4.3 SOUTH KOREA
- 8.4.4 AUSTRALIA
- 8.4.5 REST OF ASIA-PACIFIC
8.5 REST OF THE WORLD
- 8.5.1 MIDDLE EAST
- 8.5.2 AFRICA
- 8.5.3 LATIN AMERICA

9 COMPETITIVE LANDSCAPE

9.1 OVERVIEW
9.2 COMPETITIVE BENCHMARKING
9.3 MAJOR GROWTH STRATEGY IN GLOBAL BIODEFENSE MARKET
9.4 THE LEADING PLAYER IN TERMS OF NUMBER OF DEVELOPMENTS IN THE GLOBAL BIODEFENSE MARKET
9.5 KEY DEVELOPMENT ANALYSIS
9.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
- 9.6.1 PRODUCT LAUNCH/ PRODUCT APPROVAL
- 9.6.2 PARTNERSHIP/COLLABORATION/AGREEMENT
- 9.6.3 ACQUISITION/EXPANSION/INVESTMENT
9.7 MAJOR PLAYERS FINANCIAL
- 9.7.1 SALES,
- 9.7.2 RESEARCH & DEVELOPMENT EXPENDITURE (USD MILLION),

10 COMPANY PROFILE

10.1 EMERGENT
- 10.1.1 COMPANY OVERVIEW
- 10.1.2 FINANCIAL OVERVIEW
- 10.1.3 PRODUCTS OFFERED
- 10.1.4 KEY DEVELOPMENTS
- 10.1.5 SWOT ANALYSIS
- 10.1.6 KEY STRATEGIES
10.2 BAVARIAN NORDIC
- 10.2.1 COMPANY OVERVIEW
- 10.2.2 FINANCIAL OVERVIEW
- 10.2.3 PRODUCTS OFFERED
- 10.2.4 KEY DEVELOPMENTS
- 10.2.5 SWOT ANALYSIS
- 10.2.6 KEY STRATEGIES
10.3 ALTIMMUNE
- 10.3.1 COMPANY OVERVIEW
- 10.3.2 FINANCIAL OVERVIEW
- 10.3.3 PRODUCTS OFFERED
- 10.3.4 KEY DEVELOPMENTS
- 10.3.5 KEY STRATEGIES
10.4 DYNAVAX TECHNOLOGIES
- 10.4.1 COMPANY OVERVIEW
- 10.4.2 FINANCIAL OVERVIEW
- 10.4.3 PRODUCTS OFFERED
- 10.4.4 KEY DEVELOPMENTS
- 10.4.5 KEY STRATEGIES
10.5 SIGA TECHNOLOGIES
- 10.5.1 COMPANY OVERVIEW
- 10.5.2 FINANCIAL OVERVIEW
- 10.5.3 PRODUCTS OFFERED
- 10.5.4 KEY DEVELOPMENTS
- 10.5.5 SWOT ANALYSIS
- 10.5.6 KEY STRATEGIES
10.6 ELUSYS THERAPEUTICS, INC.
- 10.6.1 COMPANY OVERVIEW
- 10.6.2 FINANCIAL OVERVIEW
- 10.6.3 PRODUCTS OFFERED
- 10.6.4 KEY DEVELOPMENTS
- 10.6.5 KEY STRATEGIES
10.7 FABENTECH BIOTECH
- 10.7.1 COMPANY OVERVIEW
- 10.7.2 FINANCIAL OVERVIEW
- 10.7.3 PRODUCTS OFFERED
- 10.7.4 KEY DEVELOPMENTS
- 10.7.5 SWOT ANALYSIS
- 10.7.6 KEY STRATEGIES
10.8 CLEVELAND BIOLABS, INC.
- 10.8.1 COMPANY OVERVIEWS
- 10.8.2 FINANCIAL OVERVIEW
- 10.8.3 PRODUCTS OFFERED
- 10.8.4 KEY DEVELOPMENTS
- 10.8.5 KEY STRATEGIES
10.9 OLOGY BIOSERVICES, INC.
- 10.9.1 COMPANY OVERVIEW
- 10.9.2 FINANCIAL OVERVIEW
- 10.9.3 PRODUCTS OFFERED
- 10.9.4 KEY DEVELOPMENTS
- 10.9.5 KEY STRATEGIES
10.10 NOVAVAX, INC.
- 10.10.1 COMPANY OVERVIEW
- 10.10.2 FINANCIAL OVERVIEW
- 10.10.3 PRODUCTS OFFERED
- 10.10.4 KEY DEVELOPMENTS
- 10.10.5 SWOT ANALYSIS
- 10.10.6 KEY STRATEGIES

11 APPENDIX

11.1 REFERENCES
11.2 RELATED REPORTS

バイオディフェンスの世界市場：疾病タイプ・治療・地域別の予測 (～2030年)

Global Biodefense Market Research Report Information by Disease Type by Treatment, by Region - Forecast till 2030

目次

第1章エグゼクティブサマリー

第2章市場概要

第3章調査手法

第4章市場力学

第5章市場要因分析

第6章世界のバイオディフェンス市場：疾病タイプ別

第7章世界のバイオディフェンス市場：治療別

第8章世界のバイオディフェンス市場：地域別

第9章競合情勢

第10章企業プロファイル

第11章付録

LIST OF TABLES

LIST OF FIGURES

Market Overview

Major Players

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

3 RESEARCH METHODOLOGY

4 MARKET DYNAMICS

5 MARKET FACTOR ANALYSIS

6 GLOBAL BIODEFENSE MARKET, BY DISEASE TYPE

7 GLOBAL BIODEFENSE MARKET, BY TREATMENT

8 GLOBAL BIODEFENSE MARKET, BY REGION

9 COMPETITIVE LANDSCAPE

10 COMPANY PROFILE

11 APPENDIX

バイオディフェンスの世界市場：疾病タイプ・治療・地域別の予測 (～2030年)

Global Biodefense Market Research Report Information by Disease Type by Treatment, by Region - Forecast till 2030

目次

第1章 エグゼクティブサマリー

第2章 市場概要

第3章 調査手法

第4章 市場力学

第5章 市場要因分析

第6章 世界のバイオディフェンス市場：疾病タイプ別

第7章 世界のバイオディフェンス市場：治療別

第8章 世界のバイオディフェンス市場：地域別

第9章 競合情勢

第10章 企業プロファイル

第11章 付録

LIST OF TABLES

LIST OF FIGURES

Market Overview

Major Players

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

3 RESEARCH METHODOLOGY

4 MARKET DYNAMICS

5 MARKET FACTOR ANALYSIS

6 GLOBAL BIODEFENSE MARKET, BY DISEASE TYPE

7 GLOBAL BIODEFENSE MARKET, BY TREATMENT

8 GLOBAL BIODEFENSE MARKET, BY REGION

9 COMPETITIVE LANDSCAPE

10 COMPANY PROFILE

11 APPENDIX

第1章エグゼクティブサマリー

第2章市場概要

第3章調査手法

第4章市場力学

第5章市場要因分析

第6章世界のバイオディフェンス市場：疾病タイプ別

第7章世界のバイオディフェンス市場：治療別

第8章世界のバイオディフェンス市場：地域別

第9章競合情勢

第10章企業プロファイル

第11章付録